IN2012DN00767A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00767A
IN2012DN00767A IN767DEN2012A IN2012DN00767A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A IN 767DEN2012 A IN767DEN2012 A IN 767DEN2012A IN 2012DN00767 A IN2012DN00767 A IN 2012DN00767A
Authority
IN
India
Prior art keywords
therapy
initiation
tools
response
serum
Prior art date
Application number
Other languages
English (en)
Inventor
Visvanathan Sudha
Wagner Carrie
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of IN2012DN00767A publication Critical patent/IN2012DN00767A/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/92—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving lipids, e.g. cholesterol, lipoproteins, or their receptors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/52—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving transaminase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/475—Assays involving growth factors
    • G01N2333/485—Epidermal growth factor [EGF] (urogastrone)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/525—Tumor necrosis factor [TNF]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G01N2333/70539—MHC-molecules, e.g. HLA-molecules
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/91—Transferases (2.)
    • G01N2333/91188—Transferases (2.) transferring nitrogenous groups (2.6)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/916—Hydrolases (3) acting on ester bonds (3.1), e.g. phosphatases (3.1.3), phospholipases C or phospholipases D (3.1.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
IN767DEN2012 2009-07-28 2010-07-12 IN2012DN00767A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22899409P 2009-07-28 2009-07-28
PCT/US2010/041714 WO2011014349A1 (en) 2009-07-28 2010-07-12 Serum markers predicting clinical response to anti-tnfalpha antibodies in patients with psoriatic arthritis

Publications (1)

Publication Number Publication Date
IN2012DN00767A true IN2012DN00767A (pt) 2015-06-26

Family

ID=43529642

Family Applications (1)

Application Number Title Priority Date Filing Date
IN767DEN2012 IN2012DN00767A (pt) 2009-07-28 2010-07-12

Country Status (7)

Country Link
US (1) US20120178100A1 (pt)
EP (1) EP2460007A4 (pt)
CN (1) CN102576015B (pt)
AU (1) AU2010276665A1 (pt)
CA (1) CA2769462A1 (pt)
IN (1) IN2012DN00767A (pt)
WO (1) WO2011014349A1 (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2679995T3 (es) 2011-03-11 2018-09-03 Vib Vzw Moléculas y métodos para la inhibición y detección de proteínas
RU2014125071A (ru) * 2011-11-21 2015-12-27 Новартис Аг Способы лечения псориатического артрита (psa) с использованием антагонистов il-17 и аллелей ответа psa или отсутствия ответа psa
FR3010188B1 (fr) * 2013-09-05 2017-11-24 Univ Joseph Fourier - Grenoble 1 Procede theragnostique pour le traitement des rhumatismes inflammatoires chroniques
ES3041639T3 (en) * 2015-09-29 2025-11-13 Univ California Biomarkers and methods for assessing psoriatic arthritis disease activity
US20190148019A1 (en) * 2016-05-12 2019-05-16 Hoffmann-La Roche Inc. System for predicting efficacy of a target-directed drug to treat a disease
CN109580759A (zh) * 2017-09-28 2019-04-05 成都飞机工业(集团)有限责任公司 一种四极质谱计
US11232344B2 (en) 2017-10-31 2022-01-25 General Electric Company Multi-task feature selection neural networks
US12089930B2 (en) 2018-03-05 2024-09-17 Marquette University Method and apparatus for non-invasive hemoglobin level prediction
KR20210118878A (ko) * 2019-01-23 2021-10-01 얀센 바이오테크 인코포레이티드 건선성 관절염의 치료 방법에 사용하기 위한 항-tnf 항체 조성물
WO2022051245A2 (en) * 2020-09-01 2022-03-10 Scipher Medicine Corporation Methods and systems for predicting response to anti-tnf therapies
CN114518416B (zh) * 2020-11-20 2024-05-24 上海交通大学医学院附属瑞金医院 一种判断银屑病对il-17a抗体应答反应及其复发的标志物
EP4264272B1 (en) * 2020-12-18 2024-09-18 Nightingale Health Oyj Method for determining whether a subject is at risk of developing a musculoskeletal and/or connective tissue disease
CA3208411A1 (en) * 2021-02-25 2022-09-01 George C. Lee Patient response-based biomarker topology quantification and assessment for multiple tissue types

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002048310A2 (en) * 2000-12-15 2002-06-20 Genetics Institute, Llc Methods and compositions for diagnosing and treating rheumatoid arthritis
US20080026485A1 (en) * 2006-04-18 2008-01-31 Wolfgang Hueber Antibody profiling for determination of patient responsiveness
TWI500427B (zh) * 2010-05-14 2015-09-21 Abbvie Inc Il-1結合蛋白

Also Published As

Publication number Publication date
EP2460007A4 (en) 2013-06-19
CA2769462A1 (en) 2011-02-03
CN102576015A (zh) 2012-07-11
CN102576015B (zh) 2014-09-10
US20120178100A1 (en) 2012-07-12
EP2460007A1 (en) 2012-06-06
AU2010276665A1 (en) 2012-02-23
WO2011014349A1 (en) 2011-02-03

Similar Documents

Publication Publication Date Title
MX2018012580A (es) Métodos y kits para el diagnóstico y la estratificación de riesgo en pacientes con isquemia.
BR112015017403A2 (pt) biomarcadores de terapia de combinação de anti-tnf e anti-il17 para doença inflamatória
IN2014CN04326A (pt)
BR112014031365A2 (pt) métodos de detectar doenças ou condições
BR112015025407A2 (pt) método e dispositivo para testar um transformador
MX360564B (es) Análisis de coagulación de bajo volumen.
WO2008036835A3 (en) Methods and compositions for upregulation of peroxiredoxin activity
BR112015029852A2 (pt) método para prever ou monitorar se um paciente que sofre de câncer ou uma doença autoimune responderá ou responde ao tratamento com um agonista de tlr-9, agonista de tlr-9 para uso em um método de tratamento de câncer, e kit para prever ou monitorar se um paciente que sofre de câncer ou doença autoimune irá responder ou responde ao tratamento com um agonista de tlr-9
BR112013000869A2 (pt) método para diagnóstico de câncer de próstata (pca) com uma sensibilidade desejada em um sujeito; método para monitorar a progressão do câncer de próstata (pca) em um sujeito; método para avaliar se um sujeito tem que ser submetido a uma biópsia de próstata; kit compreendendo um primeiro componente e, opcionalmente, um segundo componente e uso de um kit
MX2017010569A (es) Dispositivo, plataforma y ensayo para evaluacion de celulas.
BR112015004631A2 (pt) marcadores genéticos de resistência à mastite
BR112013004254A2 (pt) conjunto, método, sistema, e aparelho para avaliação do nível de partículas de lipoproteína específicas presentes em um fluido corporal
BR112018003300A2 (pt) sistemas e métodos para determinar informação relacionada a uma ordem atual com base em ordens históricas
BR112015021507A2 (pt) métodos e composições para o diagnóstico de pré-eclampsia
BR112012024175A2 (pt) hbf e a1m como marcadores de estágio precoce para preeclampsia
BR112014018717A8 (pt) Método para selecionar ou identificar um sujeito para terapia de antagonista de v1b
BR112013025287A2 (pt) ensaios com receptores de esteroide para detectar células tumorais
BR112021021574A2 (pt) Método para identificar uma abordagem reprodutiva em um indivíduo que sofre de uma varicocele
PL419784A1 (pl) Zastosowanie metabolitów jako biomarkerów do przewidywania porodu przedwczesnego i sposób identyfikacji porodu przedwczesnego
UA109274U (uk) Спосіб прогнозування розвитку остеопорозу
UA128823U (uk) Спосіб прогнозування розвитку остеоартрозу
UA108612U (uk) Спосіб прогнозування розвитку остеопорозу
UA130515U (uk) Спосіб прогнозування розвитку остеоартрозу
UA82147U (ru) Способ прогнозирования риска возникновения ишемического инсульта
Morin et al. Advanced paternal age does not affect embryo development in preimplantation genetic screening cycles